KV Pharmaceuticals Case Study Essay

3983 Words16 Pages
Introduction Business ethics is an extremely important topic in our world today. This is especially true because of the fact that we live in a changing society where it has become increasingly common to see more and more cases of companies that participate in illegal, immoral and unethical activities. So that we can prevent these behaviors, it is necessary to study and understand how these situations can occur and what we can do to prevent them from happening. In this research paper, we will examine in detail the case of KV Pharmaceuticals, also known as KV. We will discuss a few major areas of topic that include how and why these events took place, as well as what could have been done to prevent them. Next, we will take a look at…show more content…
One month later, KV decided to recall some of the morphine sulfate it had distributed, and it also filed a field alert report to the FDA informing them about their recall. KV immediately began an internal investigation of their manufacturing process and their products; the investigation revealed that not only were the morphine sulfate pills oversized, but the propafenone and dextroamphetamine sulfate tablets as well. These oversized tablets can result in the patients receiving almost twice the amount of the recommended dose, which can lead to fatal consequences. Propafenone is an anti-arrhythmic medication that treats illnesses associated with heart palpitations. An overdose can cause low blood pressure or heart palpitations which may lead to death. Dextroamphetamine sulfate is used to treat narcolepsy, ADHD in children, epilepsy and parkinsonism; an overdose can lead to fatal poisoning (KV Pharmaceutical, 2010).
The complaints led to the inspection of KV by the FDA from December 2008 to February 2009; the inspection results confirmed that KV Pharmaceuticals had a considerable amount of cGMP violations, and even then they decided to manufacture unapproved drugs. While conducting the inspection, the FDA also realized that ETHEX had never filed the field alert reports concerning the oversized propafenone and dextroamphetamine sulfate tablets, which is required under the Food, Drug, and Cosmetic Act. This Act states that drug manufacturers must carefully
Get Access